2.2. Anlisis del desempeo de la firma (85 puntos) Anlisis del desempeo de la Firma Antonio Rodrguez Villanueva / # 1610636730 MBA5050-5009ONL, NUC University NBCTO-2020-4CC: Anlisis de los Estados Financieros Prof.: Dr. Juan Otero Serrano 07 / 12 / 2020 2.2. Anlisis del desempeo de la firma (85 puntos) Tabla 1: Company Name: .............. Solvency or Debt Ratios Year 2018 Merck J&J Debt ratio .... .... Debt-to-equity ratio .... .... Interest coverage ratio .... .... Liquidity Ratios Current ratio .... .... Quick ratio .... .... Cash ratio .... .... Profitability Ratios Profit margin .... .... ROE (Return on equity), after tax .... .... ROA (Return on assets) .... .... Gross margin .... .... Operating margin (Return on sales) .... .... Activity or Efficiency Ratios Asset turnover .... .... Receivables turnover (days) .... .... Inventory turnover (days) .... .... Price Ratios Dividend Payout Ratio .... .... Chemicals and Allied Products Industry Ratios 2018 0.47 0.38 -9.43 3.47 2.12 2.24 -93.4% -248.5 -146.5 55.3% -42.9% 1.08 16 36 0.15 2.2. Anlisis del desempeo de la firma (85 puntos) Estados Financieros Johnson & Johnson (JNJ) Balance Sheet December 31, 2018 ($ in millions) ASSETS Current Assets Cash, cash equivalents and short-term investments $19,687 Receivables 14,098 Inventory 9,549 Other current assets 2,699 Total Current Assets: 46,033 Noncurrent Assets Property, plant and equipment, net 17,035 Net Intangible assets (including goodwill) 78,064 Other noncurrent assets 11,822 Total Noncurrent Assets: 106,921 TOTAL ASSETS: $152,954 LIABILITIES AND EQUITY Liabilities Current Liabilities Accounts Payable 7,537 Accrued liabilities 11,517 Short term debt 2,800 Other noncurrent liabilities 9,376 Total current liabilities: Noncurrent Liabilities 31,230 2.2. Anlisis del desempeo de la firma (85 puntos) Long-term debt and lease obligation 27,684 Liabilities, other than long-term debt (pension, 0deferred tax, other) 34,288 Total noncurrent liabilities: 61,972 TOTAL LIABILITIES: 93,202 Stockholders'equity Common stock 3,120 Treasury stock, value -34,362 Accumulated other comprehensive loss -15,222 Retained earnings 106,216 Total stockhholders'equity 59,752 Total Liabilities and Stockholders'Equity: $152,954 Johnson & Johnson (JNJ) Income Statement For period ending December 31, 2018 ($ in millions) Revenues Revenues, net Cost of Revenue Gross profit: Operating Expenses Operating Income: Nonoperating income (expense) Interest and debt expense Income from continuing operations before income taxes: Income tax expense Net Income available to stockholder Dividends paid to Stockholders Retained Earnings $81,581 -27,091 54,490 -34,692 19,798 -794 -1,005 17,999 -2,702 $15,297 -9,494 $5,803 2.2. Anlisis del desempeo de la firma (85 puntos) ` Merck & Company, Inc. (MRK) Balance Sheet December 31, 2018 ($ in millions) ASSETS Current Assets Cash, cash equivalents and short-term investments Receivables Inventory Other current assets Total Current Assets: $8,864 7,071 5,440 4,500 25,875 Total Noncurrent Assets: TOTAL ASSETS: 13,291 29,684 13,787 56,762 $82,637 Noncurrent Assets Property, plant and equipment, net Net Intangible assets (including goodwill) Other noncurrent assets LIABILITIES AND EQUITY 2.2. Anlisis del desempeo de la firma (85 puntos) Liabilities Current Liabilities Accounts Payable Accrued liabilities Short term debt Other noncurrent liabilities 3,318 3,429 5,308 10,151 22,206 Total current liabilities: Noncurrent Liabilities Long-term debt and lease obligation Liabilities, other than long-term debt (pension, defferred tax, other) Total noncurrent liabilities: TOTAL LIABILITIES: Stockholders'equity Common stock Treasury stock, value Additional paid in capital Accumulated other comprehensive loss Retained earnings Stockholders'equity attributable to noncontrolling interest Total stockhholders'equity Total Liabilities and Stockholders'Equity: 19,806 13,743 33,549 55,755 1,788 -50,929 38,808 -5,545 42,579 181 26,882 $82,637 Merck & Company, Inc. (MRK) Income Statement For period ending December 31, 2018 ($ in millions) Revenues Revenues, net Cost of Revenue Gross profit: Operating Expenses Operating Income: Nonoperating income (expense) Interest and debt expense Other undisclosed income (loss) from continuing operations before income taxes: Income from continuing operations before income taxes: Income tax expense Net Income available to stockholder Dividends paid to Stockholders $42,294 -13,509 28,785 -20,486 8,299 402 -772 772 8,701 -2,508 $6,193 -5,172 2.2. Anlisis del desempeo de la firma (85 puntos) Retained Earnings Rev. abril 2020 Dr. Otero $1,021